Cargando…

Systems and synthetic biology-driven engineering of live bacterial therapeutics

The past decade has seen growing interest in bacterial engineering for therapeutically relevant applications. While early efforts focused on repurposing genetically tractable model strains, such as Escherichia coli, engineering gut commensals is gaining traction owing to their innate capacity to sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Kangsan, Kang, Minjeong, Cho, Byung-Kwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620806/
https://www.ncbi.nlm.nih.gov/pubmed/37929193
http://dx.doi.org/10.3389/fbioe.2023.1267378
_version_ 1785130280814641152
author Kim, Kangsan
Kang, Minjeong
Cho, Byung-Kwan
author_facet Kim, Kangsan
Kang, Minjeong
Cho, Byung-Kwan
author_sort Kim, Kangsan
collection PubMed
description The past decade has seen growing interest in bacterial engineering for therapeutically relevant applications. While early efforts focused on repurposing genetically tractable model strains, such as Escherichia coli, engineering gut commensals is gaining traction owing to their innate capacity to survive and stably propagate in the intestine for an extended duration. Although limited genetic tractability has been a major roadblock, recent advances in systems and synthetic biology have unlocked our ability to effectively harness native gut commensals for therapeutic and diagnostic purposes, ranging from the rational design of synthetic microbial consortia to the construction of synthetic cells that execute “sense-and-respond” logic operations that allow real-time detection and therapeutic payload delivery in response to specific signals in the intestine. In this review, we outline the current progress and latest updates on microbial therapeutics, with particular emphasis on gut commensal engineering driven by synthetic biology and systems understanding of their molecular phenotypes. Finally, the challenges and prospects of engineering gut commensals for therapeutic applications are discussed.
format Online
Article
Text
id pubmed-10620806
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106208062023-11-03 Systems and synthetic biology-driven engineering of live bacterial therapeutics Kim, Kangsan Kang, Minjeong Cho, Byung-Kwan Front Bioeng Biotechnol Bioengineering and Biotechnology The past decade has seen growing interest in bacterial engineering for therapeutically relevant applications. While early efforts focused on repurposing genetically tractable model strains, such as Escherichia coli, engineering gut commensals is gaining traction owing to their innate capacity to survive and stably propagate in the intestine for an extended duration. Although limited genetic tractability has been a major roadblock, recent advances in systems and synthetic biology have unlocked our ability to effectively harness native gut commensals for therapeutic and diagnostic purposes, ranging from the rational design of synthetic microbial consortia to the construction of synthetic cells that execute “sense-and-respond” logic operations that allow real-time detection and therapeutic payload delivery in response to specific signals in the intestine. In this review, we outline the current progress and latest updates on microbial therapeutics, with particular emphasis on gut commensal engineering driven by synthetic biology and systems understanding of their molecular phenotypes. Finally, the challenges and prospects of engineering gut commensals for therapeutic applications are discussed. Frontiers Media S.A. 2023-10-19 /pmc/articles/PMC10620806/ /pubmed/37929193 http://dx.doi.org/10.3389/fbioe.2023.1267378 Text en Copyright © 2023 Kim, Kang and Cho. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Kim, Kangsan
Kang, Minjeong
Cho, Byung-Kwan
Systems and synthetic biology-driven engineering of live bacterial therapeutics
title Systems and synthetic biology-driven engineering of live bacterial therapeutics
title_full Systems and synthetic biology-driven engineering of live bacterial therapeutics
title_fullStr Systems and synthetic biology-driven engineering of live bacterial therapeutics
title_full_unstemmed Systems and synthetic biology-driven engineering of live bacterial therapeutics
title_short Systems and synthetic biology-driven engineering of live bacterial therapeutics
title_sort systems and synthetic biology-driven engineering of live bacterial therapeutics
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620806/
https://www.ncbi.nlm.nih.gov/pubmed/37929193
http://dx.doi.org/10.3389/fbioe.2023.1267378
work_keys_str_mv AT kimkangsan systemsandsyntheticbiologydrivenengineeringoflivebacterialtherapeutics
AT kangminjeong systemsandsyntheticbiologydrivenengineeringoflivebacterialtherapeutics
AT chobyungkwan systemsandsyntheticbiologydrivenengineeringoflivebacterialtherapeutics